The MSI-IVD Kit (Falco), which detects MSI-High within tumor tissues as a biomarker of DNA repair dysfunction, is the first pan-tumor companion diagnostic test in Japan. Its intended use is to identify patients suitable for treatment with the anti-PD-1 antibody "Keytruda" (Pembrolizumab).
The Falco kit detects MSI-High status with DNA isolated only from a patient's tumor tissue, without corresponding submission of a blood sample, using multiplex PCR fragment analysis with Promega designed five mononucleotide repeat markers, which are less susceptible to genetic polymorphisms.
The clinical performance study conducted for the kit confirmed the detection capability of MSI-High in 16 different cancer types for stomach, uterine, breast, pancreas, etc. other than colorectal cancer.
Promega MSI technology uses the same loci that have been validated in labs around the world and is the gold standard in nucleic acid based MSI testing.
A 2018 College of American Pathologists survey indicated that 70% of respondents performing nucleic acid based MSI testing were doing so using the Promega MSI 1.2 panel of loci.
Promega Corp.'s latest MSI technology was recently granted innovation designation by the Chinese National Medical Products Administration and the company intends to seek US Food and Drug Administration approval for IVD status of its MSI 1.2 platform.
Promega Corp. is in providing solutions and technical support to the life sciences industry. The company's 4,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, drug discovery and human identification.
Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT